Table 2.

Variable impact on participants’ responses.

Question: What is the likelihood of prescribing a biosimilar to an eligible rheumatic disease patient at the current moment?
Variable	Odds ratio	CI	p value
Male gender	1.553	0.728–3.311	0.255
Non-Saudi nationality	1.175	0.426–3.238	0.756
Adult specialty	2.183	0.84–5.677	0.109
Consultant status	1.18	0.473–2.944	0.722
Type of practice
Academic	1.169	0.499–2.737	0.72
Military	3.901	1.334–11.407	0.013
Private practice	2.975	0.754–11.735	0.119
Constant	0.364	–	0.113
Do you have a clear understanding on the concept of totality of evidence regarding the approval process of biosimilars?
Variable	Odds ratio	CI	p value
Male gender	0.766	0.358–1.637	0.491
Non-Saudi nationality	0.409	0.149–1.127	0.084
Adult specialty	0.571	0.211–1.549	0.271
Consultant status	0.366	0.13–1.031	0.057
Question: Do you believe that non-medical switching could be harmful?
Variable	Odds ratio	CI	p value
Female gender	1.847	0.86–3.965	0.116
Non-Saudi nationality	1.727	0.616–4.842	0.299
Adult specialty	1.043	0.403–2.699	0.93
Consultant status	1.368	0.544–3.437	0.505
Type of practice
Academic	0.758	0.326–1.764	0.52
Military	2.386	0.865–6.581	0.093
Private practice	1.55	0.396–6.067	0.529
Constant	0.706	–	0.616
Question: Do you believe that non-medical switching could lead to significant cost-savings?
Variable	Odds ratio	CI	p value
Female gender	1.418	0.669–3.002	0.362
Saudi nationality	1.093	0.416–2.869	0.857
Pediatric specialty	1.341	0.514–3.5	0.548
Trainee status	1.789	0.679–4.716	0.239
Type of practice
Academic	0.705	0.282–1.764	0.455
Military	2.232	0.884–5.635	0.089
Private practice	1.4	0.394–4.97	0.603
Constant	0.952	–	0.925